Hospital
Broaddus Hospital Association, INC.
Broaddus Hospital Association, INC. was paid $7.31M by Medicaid between Jan 2018 and Nov 2024, across 95 billing codes. Its largest line is 99283, emergency room visit (moderate) — 29% of everything it billed.
33Billing provider infoBROADDUS HOSPITAL ASSOCIATION, INC.
PHILIPPI, WV 26416
PHILIPPI, WV 26416
33aNPI1548246622assigned 12/20/2005
33bProvider typeCritical Access Hospital
28Total paid$7.31M
24GClaims123,496
24DCodes billed95
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Critical Access Hospital providers in West Virginia
Rank by total paid#8 of 24
Median peer was paid$3.57M
This provider vs. median2.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 22,208 | $1.49M | |
| 2019 | 15,458 | $1.08M | |
| 2020 | 23,342 | $1.49M | |
| 2021 | 20,166 | $1.01M | |
| 2022 | 15,322 | $832K | |
| 2023 | 14,218 | $681K | |
| 2024incomplete | 12,782 | $721K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 29% | 15,258 | 12,205 | $2.13M |
| 80053 | Comprehensive metabolic panel | 7.1% | 10,069 | 8,411 | $518K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 4.7% | 2,564 | 1,740 | $341K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 4.5% | 4,570 | 1,057 | $332K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 4.4% | 748 | 641 | $319K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 3.5% | 9,614 | 8,001 | $258K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.3% | 1,334 | 866 | $242K |
| 84443 | Thyroid stimulating hormone (TSH) | 2.8% | 4,325 | 3,811 | $206K |
| 81001 | 2.0% | 4,381 | 3,644 | $147K | |
| 70450 | Computed tomography, head or brain; without contrast material | 1.9% | 434 | 349 | $136K |
| 80061 | Lipid panel | 1.8% | 2,694 | 2,489 | $133K |
| 87428 | 1.8% | 2,936 | 2,517 | $129K |
83 more codes
| 83605 | 1.7% | 2,226 | $124K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 1.5% | 3,490 | $112K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.5% | 2,724 | $110K |
| 36415 | Collection of venous blood by venipuncture | 1.5% | 7,701 | $108K |
| 71045 | Radiologic examination, chest; single view | 1.3% | 1,723 | $93K |
| 71046 | Radiologic examination, chest; 2 views | 1.2% | 1,091 | $90K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.1% | 1,061 | $82K |
| 84484 | 1.1% | 2,580 | $77K | |
| 83036 | Hemoglobin; glycosylated (A1C) | 1.0% | 1,879 | $75K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 1,324 | $69K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,186 | $67K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 403 | $66K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,020 | $64K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 735 | $61K |
| 82550 | <1% | 2,171 | $60K | |
| 83735 | <1% | 2,213 | $59K | |
| 82553 | <1% | 1,321 | $58K | |
| 87088 | <1% | 1,392 | $53K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 597 | $50K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,370 | $50K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 749 | $47K |
| 85610 | <1% | 1,834 | $45K | |
| 82607 | <1% | 646 | $45K | |
| 85027 | <1% | 1,166 | $44K | |
| 85007 | <1% | 1,150 | $40K | |
| 87420 | <1% | 734 | $38K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 2,772 | $38K |
| 85730 | <1% | 1,297 | $37K | |
| 83690 | <1% | 804 | $35K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 2,367 | $34K |
| 80306 | <1% | 314 | $30K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 715 | $29K |
| 85378 | <1% | 689 | $29K | |
| 87040 | <1% | 574 | $25K | |
| 82150 | <1% | 577 | $24K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 688 | $24K |
| 84439 | <1% | 508 | $23K | |
| 87631 | <1% | 130 | $21K | |
| 83880 | <1% | 374 | $17K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 315 | $16K |
| 81025 | <1% | 326 | $16K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 99 | $15K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 410 | $13K |
| 86140 | <1% | 538 | $13K | |
| 87077 | <1% | 425 | $13K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 132 | $12K |
| 80050 | General health panel | <1% | 89 | $11K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 644 | $11K |
| 87186 | <1% | 359 | $10K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 61 | $9K |
| 86141 | <1% | 248 | $9K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 249 | $9K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 62 | $8K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 294 | $8K |
| 82570 | <1% | 256 | $8K | |
| 82803 | <1% | 146 | $8K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 319 | $7K |
| 84481 | <1% | 123 | $7K | |
| 82043 | <1% | 182 | $7K | |
| 97014 | <1% | 122 | $6K | |
| 74018 | <1% | 74 | $6K | |
| 97162 | <1% | 68 | $5K | |
| 85651 | <1% | 247 | $4K | |
| 73630 | <1% | 46 | $4K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 972 | $4K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 609 | $2K |
| 97035 | <1% | 47 | $2K | |
| 71250 | <1% | 17 | $2K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 304 | $2K |
| 73610 | <1% | 19 | $2K | |
| 73564 | <1% | 16 | $2K | |
| 87070 | <1% | 51 | $2K | |
| 36600 | <1% | 41 | $1K | |
| 72100 | <1% | 13 | $1K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 85 | $1K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 45 | $917.20 |
| 83655 | <1% | 14 | $498.00 | |
| 84482 | <1% | 13 | $471.52 | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 31 | $387.17 |
| 87081 | <1% | 12 | $378.00 | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 100 | $376.85 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 30 | $265.64 |
| 99307 | 0% | 21 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGOULD, DANA (CEO)
| Provider | Location | Paid |
|---|---|---|
| Broaddus Hospital Group | Philippi, WV | $13K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.